Exxel Pharma Inc.
Preclinical biotech seeking $13M IPO to fund first human trial of a cough drug.
On the record
Checkpoint: Planned first-in-human Phase 1/1b trial of EX937 begins in Australia
The call
Exxel is a one-employee company betting its entire IPO raise on a single unproven drug, racing rivals that already have approved or late-stage competitors.
Exxel Pharma is a one-person company trying to raise $13.2 million to run its first human trial of a cough medicine called EX937. The drug targets the same problem that Merck's already-approved Lyfnua and GSK's camlipixant (further along in testing) are trying to solve, and similar drugs in this class have failed before, so it is uncertain whether EX937 will even work safely in people. The company will either succeed or fail based entirely on what happens in the next 12 to 18 months: if the IPO doesn't close or if the early trial results show safety problems, the company likely runs out of money and ends.
Why
01
AI pressure: None apparent. No AI product competes here; the risk is a failed FAAH molecule, not software or automation. Could AI do the core job? Unlikely.
02
Bigger players: Merck & Co. (Lyfnua/gefapixant) and GSK/Bellus (camlipixant, Phase 3). Merck already sells an approved chronic-cough drug; GSK's rival compound is in late-stage trials years ahead of Exxel's. Could a giant copy it? Yes, easily.
03
What protects it. A UC Irvine license on a peripherally restricted FAAH inhibitor, untested in any human until Phase 1 starts.
What would change this call
Whether Exxel's NYSE American IPO actually prices and closes. Shows whether Exxel secures the ~$13.2M needed to fund any clinical work at all.
Whether EX937 Phase 1/1b trial initiates in Australia in 2026. Shows whether Exxel can even begin human testing on its planned timeline.
Whether GSK/Bellus reports camlipixant Phase 3 SOOTHE data before Exxel's Phase 1 readout. Would show a much larger rival reaching approval well ahead of Exxel.
Whether EX937 Phase 1/1b trial initiates in Australia in 2026. Shows whether Exxel can even begin human testing on its planned timeline.
Whether GSK/Bellus reports camlipixant Phase 3 SOOTHE data before Exxel's Phase 1 readout. Would show a much larger rival reaching approval well ahead of Exxel.
Key numbers
- $13.2M IPO target: 3M shares at $5
- $3.8M of proceeds earmarked for Phase 1 trial
- $11B estimated market for chronic cough
Named risks
- IPO may fail to price or complete, leaving Exxel without funding for Phase 1.
- FAAH inhibitor class has history of clinical failures, including a fatal trial (BIA 10-2474).
- Thin capital runway: $13.2M target raise against $3.8M Phase 1 budget plus overhead.
- Key-person concentration with ~1 employee and CSO simultaneously CEO of another company.
- Years behind approved and Phase 3 rival mechanisms (Merck, GSK) in same indication.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Merck & Co. (gefapixant/Lyfnua) | losing to | Gefapixant already approved and marketed for chronic cough as of Nov 23, 2024 |
| GSK / Bellus Health (camlipixant) | losing to | Camlipixant in Phase 3 SOOTHE trial as of Jun 18, 2026, after GSK's 2023 acquisition |
| Bayer (eliapixant) | contesting | Eliapixant completed Phase 2 for RCC as of Nov 22, 2024 |
| Shionogi (sivopixant) | contesting | Sivopixant completed Phase 2 for RCC as of Nov 22, 2024 |
Questions people ask
- Is Exxel Pharma profitable in 2026?
- No. Exxel Pharma reported trailing twelve month revenue of about $225,000 against a net loss of roughly $1.27 million, per stockanalysis.com data. The company is preclinical, with no FDA-approved product and no commercial drug sales as of February 3, 2026, so profitability is not near-term feasible.
- Has Exxel Pharma's IPO priced yet?
- As of February 19, 2026, Exxel Pharma's NYSE American IPO status was listed as 'Pending' on stockanalysis.com. A January 30, 2026 amended SEC filing set terms at 3 million shares at $5.00 each, targeting about $13.2 million gross, but completion was unconfirmed.
- What is Exxel Pharma's lead drug candidate?
- EX937 is Exxel Pharma's lead asset, an oral, peripherally restricted FAAH enzyme inhibitor licensed from UC Irvine, targeting refractory chronic cough. As of February 3, 2026 it remained preclinical, with first-in-human Phase 1/1b testing planned in Australia, not yet started.
- Who is Exxel Pharma's biggest competitor?
- Merck's gefapixant (Lyfnua) is already approved for refractory chronic cough in multiple markets as of November 23, 2024, and GSK's camlipixant (via its 2023 Bellus Health acquisition) is in Phase 3 SOOTHE trials as of June 18, 2026, both years ahead of Exxel's preclinical EX937.
- How many employees does Exxel Pharma have?
- Stockanalysis.com's company profile, dated February 19, 2026, lists Exxel Pharma's employee count as 1. The company appears to operate as a virtual, management-only biotech relying on outsourced contract research organizations to run its planned clinical trial.
- Could AI replace what Exxel Pharma does?
- No. Exxel Pharma's core work is physical and regulatory: preclinical chemistry, FDA and TGA clinical trial authorization, and a licensed composition-of-matter patent on EX937 from UC Irvine. Drug approval risk is not AI-replaceable; no evidence as of February 2026 shows Exxel using AI drug-discovery tools.
Timeline
- 2026-02-19IPO status listed as Pending on stockanalysis.com; company profile shows Aurora, CO HQ and 1 employee
- 2026-02-03FierceBiotech reports Exxel's $13M IPO plan and FAAH inhibitor class failure history
- 2026-01-30Amended S-1 sets IPO terms: 3M shares at $5, targeting $13.2M gross for NYSE American listing
- 2025-10-14Exxel Pharma files S-1/A amendment with SEC
- 2025-09-19Exxel Pharma files initial Form S-1 with SEC to list as EXXL on NYSE American
- 2025-07-22Exxel Pharma participates in Virtual Investor 'What's Your Story' conference
- 2025-03-18Share-exchange agreement redomiciles company from British Columbia to Colorado corporation
- 2025-02-03Company announces EX937 advancing toward first-in-human study, cites $11B TAM for chronic cough
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Exxel plans $13M IPO to score where other FAAH inhibitors have failed (Feb 3, 2026)
- Exxel Pharma (EXXL) Stock Price & Overview
- Exxel Pharma (EXXL) Company Profile & Description (Feb 19, 2026)
- Exxel Pharma (EXXL) Statistics & Valuation
- Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study (Feb 3, 2025)
- Exxel Pharma Participates in the Virtual Investor "What's Your Story"... (Jul 22, 2025)
- Securities Exchange Agreement between Exxel Pharma Inc. (British Columbia)... (Mar 18, 2025)
- Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough (Nov 23, 2024)
- P2X3 Receptor Antagonists in Chronic Cough (Nov 22, 2024)
- Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough (Jun 18, 2026)
- Exxel Pharma Overview, Address & Contact
- BIA 10-2474